Neurocrine Biosciences Inc (FRA:NB3) Stock News, Headlines & Updates
Neurocrine Biosciences Inc Stock News from GuruFocus
- 1
- 2
- 3
Jul 22, 2025
Neurocrine Biosciences (NBIX) Target Price Raised by Morgan Stanley | NBIX Stock News
GuruFocus News • 8:35am
Morgan Stanley Increases Price Target for Neurocrine (NBIX) to $150 | NBIX Stock News
GuruFocus News • 6:47am
Jul 21, 2025
NBIX Stock Coverage Initiated by Truist Securities with Buy Rating | NBIX Stock News
GuruFocus News • 7:32am
Neurocrine (NBIX) Coverage Initiated with Optimistic Outlook | NBIX Stock News
GuruFocus News • 5:45am
Jul 15, 2025
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition
PRNewswire • 9:00am
Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition | NBIX Stock News
GuruFocus News • 8:22am
Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Contro
GuruFocus News • 7:49am
Jul 14, 2025
Neurocrine Biosciences Inc (NBIX) Presents Promising Phase 3 Data on CRENESSITY® at ENDO 2025 | NBIX stock news
GuruFocus News • 4:09pm
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
GuruFocus News • 3:46pm
Neurocrine Biosciences (NBIX) Reports Positive Crenessity Study Results
GuruFocus News • 8:59am
Neurocrine Biosciences Inc (NBIX) Presents Promising One-Year Data on CRENESSITY® at ENDO 2025 | NBIX stock news
GuruFocus News • 8:10am
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
PRNewswire • 8:00am
Neurocrine Biosciences (NBIX) Unveils Promising Long-Term Data from CAHtalyst Study | NBIX Stock News
GuruFocus News • 7:48am
Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025 | NBIX Stock News
GuruFocus News • 7:46am
Jul 10, 2025
Goldman Sachs Initiates Coverage On Neurocrine Biosciences (NBIX) With Buy Rating | NBIX Stock News
GuruFocus News • 8:32am
Neurocrine (NBIX) Garners Buy Rating from Goldman Sachs | NBIX Stock News
GuruFocus News • 4:16am
Jul 09, 2025
Neurocrine Biosciences Inc (NBIX) Announces Q2 2025 Financial Results Conference Call and Webcast | NBIX stock news
GuruFocus News • 4:02pm
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
PRNewswire • 4:00pm
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results | NBIX Stock News
GuruFocus News • 3:18pm
UBS Boosts Neurocrine Biosciences (NBIX) Price Target to $174 | NBIX Stock News
GuruFocus News • 10:33am
Jun 30, 2025
Neurocrine Biosciences Initiates Phase 1 Clinical Study for NBIP-01435 | NBIX stock news
GuruFocus News • 4:05pm
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
PRNewswire • 4:00pm
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist | NBIX Stock News
GuruFocus News • 3:16pm
Jun 27, 2025
NBIX Reveals New Data from KINECT-HD Study Showing Benefits of INGREZZA Capsules | NBIX Stock News
GuruFocus News • 7:46am
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Ch
GuruFocus News • 7:45am
Jun 20, 2025
NBIX: New Analyses Highlight INGREZZA's Benefits for Older Adults with Tardive Dyskinesia | NBIX Stock News
GuruFocus News • 7:47am
Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskines
GuruFocus News • 7:46am
Jun 09, 2025
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX stock news
GuruFocus News • 4:08pm
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
PRNewswire • 4:00pm
Neurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock News
GuruFocus News • 3:30pm
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX Stock News
GuruFocus News • 3:15pm
Jun 02, 2025
RBC Capital Reiterates Outperform Rating for Neurocrine Biosciences (NBIX) | NBIX Stock News
GuruFocus News • 11:30am
Neurocrine (NBIX) Reports Positive Results from INGREZZA Study on Tardive Dyskinesia | NBIX Stock News
GuruFocus News • 7:50am
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dysk
GuruFocus News • 7:47am
May 30, 2025
Director Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX)
GuruFocus News • 7:02pm
May 28, 2025
Neurocrine Biosciences Inc (NBIX) Announces Positive Phase 2 Results for Schizophrenia Treatment | NBIX stock news
GuruFocus News • 4:01pm
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
PRNewswire • 4:00pm
Neurocrine (NBIX) Reports Positive Phase 2 Results for Schizophrenia Treatment | NBIX Stock News
GuruFocus News • 3:31pm
- 1
- 2
- 3
Show
Entries
Headlines
Total 0- 1
No recent news